Screening Study for Cervical Pre-cancer and Cancer Prevention in South African Women.

Recruiting

• Conditions: Cervical Cancer; High Grade Sil; CIN2
• Interventions: Other: Screening; Other: Colposcopy; Procedure: LLETZ

• Registration Number: NCT02956031
• Lead Sponsor: University of Pretoria

Brief Summary

Nearly 8 000 new cervical cancer cases are diagnosed in South Africa per year; many are still undiagnosed and about 50% of diagnosed cases succumb per year. Although the current prevalence of pre-cancer cervical disease is largely unknown, data from local studies suggest regional differences and an increase in the prevalence of cytological abnormalities when compared with historical data. Low frequency in cytology screening is the primary factor attributable to development of invasive cervical cancer and almost one-third of all cervical cancer patients had previous negative cytology. Due to the low sensitivity of cytology it can be assumed that the true prevalence of pre-cancer disease is underestimated by all available data. One round of optimal cervical cytology will detect around 50% of existing pre-cancer cervical disease as identified and proven using colposcopy and directed biopsy. It is now widely accepted that primary screening with a human papilloma virus (HPV) test can improve the sensitivity of screening and that even a single round of HPV screening can rapidly reduce the incidence of invasive cervical cancer and related mortality within a few years.

South Africa has a high prevalence of HIV infection and a delay in or failure to initiate antiretroviral therapy (ART). These facts, together with the largely unscreened status of the female population and the high incidence of cervical cancer all suggest that HPV infection and precursors to cervical cancer are both unusually common among South African women. Accurate current knowledge of the performance of newer generation HPV based screening tests in HIV-infected and general female population are essential for cost-analysis and planning for national prevention and screening programs. This study will aim to demonstrate the feasibility and efficacy of new generation HPV deoxyribonucleic acid (DNA) based screening assays in a South African setting.

The investigators hypothesize that HPV testing followed by normal and special cytology tests will be a successful screening model for a South African population.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2016-11-02
• Study First Submitted QC: 2016-11-03
• Study First Posted: 2016-11-04
• Study Start: 2016-12
• Status Verified: 2024-05
• Last Update Submitted: 2024-05-07
• Last Update Posted: 2024-05-08
• Primary Completion: 2038-12
• Study Completion: 2038-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Female
• Target Recruitment: 1500

Inclusion Criteria

• Informed consent accepted and signed
• Health seeking behaviour or request for a cervical cancer screening test
• Willing and able to receive test result by automated text message or clinic visit

Exclusion Criteria

• Current pregnancy
• Hysterectomy
• Current or previous treatment for gynaecological cancer
• Hesitant or unable to undergo screening and treatment if indicated

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
HIV pos	Screening	those who serologically tested positive for HIV
HIV pos	Colposcopy	those who serologically tested positive for HIV
HIV pos	LLETZ	those who serologically tested positive for HIV
HIV unk	LLETZ	those with no available serological test for HIV
HIV neg	Screening	those who serologically tested negative for HIV
HIV unk	Screening	those with no available serological test for HIV
HIV neg	Colposcopy	those who serologically tested negative for HIV
HIV neg	LLETZ	those who serologically tested negative for HIV
HIV unk	Colposcopy	those with no available serological test for HIV

Primary Outcome Measures

Name	Time	Method
Number of women with histologically proven cervical intraepithelial neoplasia grade 2+ (CIN2+) detected using HPV DNA analysis with partial genotyping as primary screen test followed by cervical cytology and immunocytochemistry as triage tests	Detected on histology biopsy at colposcopy after initial HPV screening with simultaneous cytology and immunocytochemistry testing

Secondary Outcome Measures

Name	Time	Method
Number of women with CIN2+ detected using HPV DNA analysis with partial genotyping that is associated with HPV types 16, 18, 16 and/or 18, only other high risk types	Detected on histology biopsy at colposcopy after initial HPV screening with simultaneous cytology and immunocytochemistry testing

Trial Locations

Locations (1)

Steve Biko Academic Hospital; 🇿🇦 Pretoria, Gauteng, South Africa